Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 20/20 | 0.61 |
| ▸ | CDK4 | P11802 | 18/20 | 0.61 |
| ▸ | CCND1 | P24385 | 18/20 | 0.61 |
| ▸ | CCNE1 | P24864 | 7/20 | 0.61 |
| ▸ | CCND3 | P30281 | 3/20 | 0.61 |
| ▸ | CDK6 | Q00534 | 3/20 | 0.61 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.61 |
| ▸ | CDK9 | P50750 | 2/20 | 0.61 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22570064 | 1.00 | CDK2 (0.61) | CDK2CDK4CCND1CCNE1CCND3 | |
| SCHEMBL22551677 | 0.92 | CDK2 (0.60) | CDK2CDK4CCND1CCNE1CCND3 | |
| SCHEMBL22551676 | 0.92 | CDK2 (0.60) | CDK2CDK4CCND1CCNE1CCND3 | |
| SCHEMBL22569966 | 0.91 | CDK2 (0.57) | CDK2CDK4CCND1CCNE1CCND3 | |
| SCHEMBL15298252 | 0.91 | CDK2 (0.56) | CDK2CDK4CCND1CCNE1CCND3 | |
| SCHEMBL18638036 | 0.91 | CDK2 (0.56) | CDK2CDK4CCND1CCNE1CCND3 | |
| SCHEMBL22551668 | 0.91 | CDK2 (0.68) | CDK2CDK4CCND1CCNE1CCND3 | |
| SCHEMBL22551658 | 0.91 | CDK2 (0.68) | CDK2CDK4CCND1CCNE1CCND3 | |
| SCHEMBL22570279 | 0.90 | CDK2 (0.58) | CDK2CDK4CCND1CCNE1CCND3 | |
| SCHEMBL22551670 | 0.90 | CDK2 (0.67) | CDK2CDK4CCND1CCNE1CCND3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230241059-A1 | ANTI-NEOPLASTIC COMBINATIONS AND DOSING REGIMENS USING CDK4/6 INHIBITOR COMPOUNDS TO TREAT RB-POSITIVE TUMORS | G1 THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | US | disclosed |
| US-11090306-B2 | Treatment of Rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors | G1 THERAPEUTICS, INC. | 2021-08-17 | — | — | US | disclosed |
| US-11040042-B2 | Transient protection of normal cells during chemotherapy | G1 THERAPEUTICS, INC. (US) | 2021-06-22 | — | — | US | disclosed |
| US-20200345742-A1 | TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY | G1 THERAPEUTICS, INC. (US) | 2020-11-05 | — | — | US | disclosed |
| US-20190151311-A1 | ANTI-NEOPLASTIC COMBINATIONS AND DOSING REGIMENS USING CDK4/6 INHIBITOR COMPOUNDS TO TREAT RB-POSITIVE TUMORS | G1 THERAPEUTICS, INC. (US) | 2019-05-23 | — | — | US | disclosed |
| EP-2831080-B1 | LACTAM KINASE INHIBITORS | TAVARES FRANCIS XAVIER (US) | 2017-03-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200345742-A1 | TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY | CDK6, CCNC, MCL1 | CDK2 10/4885CDK4 6/4885CCND1 41/4885 |
| US-20190151311-A1 | ANTI-NEOPLASTIC COMBINATIONS AND DOSING REGIMENS USING CDK4/6 INHIBITOR COMPOUNDS TO TREAT RB-POSITIVE TUMORS | CDK4, RB1, BTK | CDK2 16/4885CDK4 1/4885CCND1 47/4885 |
| US-11090306-B2 | Treatment of Rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors | RB1, CDK4, CDK6 | CDK2 18/4885CDK4 2/4885CCND1 85/4885 |
| US-20230241059-A1 | ANTI-NEOPLASTIC COMBINATIONS AND DOSING REGIMENS USING CDK4/6 INHIBITOR COMPOUNDS TO TREAT RB-POSITIVE TUMORS | CDK4, RB1, BTK | CDK2 16/4885CDK4 1/4885CCND1 47/4885 |
| US-11040042-B2 | Transient protection of normal cells during chemotherapy | CDK6, CCNC, MCL1 | CDK2 10/4885CDK4 6/4885CCND1 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.